Regeneron Pharmaceuticals Non-GAAP EPS of $11.14 beats by $1.52, revenue of $2.94B beats by $80M
Regeneron Pharmaceuticals press release  (NASDAQ:REGN): Q3  Non-GAAP EPS of $11.14  beats by $1.52.
Revenue of $2.94B (-14.8% Y/Y)  beats by $80M.
Third quarter 2022 EYLEAÂ U.S.Â net sales increased 11% versus third quarter 2021 to a record $1.63 billion
Third quarter 2022 DupixentÂ global net sales(recorded by Sanofi) increased 40% to $2.33 billion versus third quarter 2021
FY2022, the company now expects adjusted gross margin on net product sales of 92.5% to 93% from prior outlook of 92% to 93%.